MindBio Therapeutics - Marktführer bei Mircodosing LSD (Seite 2)

[evens]

Auszug aus dem aktuellen monthly progress report

MindBio announced its last participant in Phase 2a Depression trial will complete their final dosing on about 14 February 2024 and the company expects to report the results a short time later, most likely in March. Dosing continues in Phase 2b clinical trial with MB22001 in advanced stage cancer patients experiencing emotional distress. The team are preparing to begin a continuation trial, a Phase 2b Randomized Controled Depression trial on the back of Phase 2a Depression trial completion


Management is in the process of pursuing funding for new clinical trials and has had several meetings in this regard.

[evens]

Ergebnisse der 2a Studie Anfang März

Das wird dann ein Meilenstein für den Kurs - nach unten oder nach oben.

[evens]

News von letzter Woche

VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), announces it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder.

MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 (MindBio's proprietary titratable form of LSD for take-home Microdosing). The final participant in this landmark clinical trial is nearing completion and is expected to complete dosing on about 14 February 2024. Top line results from the Phase 2a Depression trial are expected to be announced to the market some-time in March 2024.

MindBio is the only company in the world to be running clinical trials with regulatory approvals for take-home use of a special form of LSD in microdoses (MB22001). Take home approvals in these trials is crucial for testing and modeling the safety and efficacy of psychedelics within the community, as MindBio works towards having these life-saving medicines globally approved for use in treating debilitating mental health conditions such as Depression. MindBio's landmark Phase 1 LSD-Microdosing clinical trial completed in 2022 showed no serious adverse events, and participants in the treatment group reported statistically significant increases in feelings of happiness, social connectivity, wellness, creativity, and energy compared to the placebo group.

MindBio's Phase 2a clinical trial in 20 patients with Major Depressive Disorder is an open label trial that will look for clinically significant improvements in depression rating scores using a global standard for measuring the severity of depression, the MADRS (Montgomery Asberg Depression Rating Scale). MB22001 is being administered in titratable microdoses to clinical trial participants. At the end of the trials, the primary end point for success is an improvement in the MADRS.

Concurrently, MindBio is conducting a Phase 2B trial in late stage cancer patients experiencing existential distress, a common phenomenon experienced at end of life, a mix of depressive and anxiety and distress symptoms that often is treated with anti-depressants. MindBio's hope is that MB22001, if proven effective in this Phase 2B randomized and double blind trial in 40 participants, will potentially be accessible to end of life patients under special drug access schemes that permit access to clinical stage experimental drugs before they are approved by regulatory bodies such as the Food & Drug Administration (FDA).

Chief Executive Officer and Co-founder of MindBio Justin Hanka said "We are looking forward to the completion of this landmark clinical trial and progressing the business towards late stage pharma drug development and commercially advancing better treatments for mental health conditions".

We invite you to join us in support of creating a brighter future for mental health.

Receive our latest updates here: https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewA…
Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

For further information, please contact:

Justin Hanka, Chief Executive Officer
61 433140886
[e-mail]

About MindBio Therapeutics

MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2a clinical trial currently underway microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial currently underway microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

[evens]

100 % sinds dann noch geworden

Ein schönes kleines Lebenszeichen.

[wallander08]

+220% aktuell in Toronto
https://thecse.com/listings/mindbio-therapeutics-corp/

[wallander08]

Vor erwartbaren "News"...zieht es zumindest an

[evens]

Jemand mit dabei?
Microdosing LSD vor der Zulassung in Australien etc. zur Behandlung von Depressionen etc.
MindBio ist hier weltweit führend.
Ein Milliardenmarkt.

130 Millionen shares. Aktuell gut 10 Millionen Dollar Marktkap..
Erst seit 4 Wochen gelistet.
Sobald hier etwas Nachfrage rein kommt bzw. ein größerer Player einsteigen will, dürfte sich MindBio schnell in anderen Kursregionen befinden